cutaneous squamous cell carcinoma
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths
Regeneron’s Libtayo receives EC approval for skin cancer
Phase 3 trial results showed the drug significantly improved disease-free survival
Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma
More than 36,000 new cases of the blood cancer are expected to be diagnosed in the US this year
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn
The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study
Regeneron to acquire human genetics company 23andMe for $256m
The agreement comes two months after 23andMe filed for bankruptcy protection
NHS programme to give melanoma patients fast-track access to skin cancer vaccine
The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma
Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma
More than 35,000 new cases of the blood cancer are diagnosed every year in Europe
Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer
Approximately 1.8 million cases of cutaneous squamous cell carcinoma are diagnosed in the US every year
Merck shares positive ten-year results for Keytruda in advanced melanoma
More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year
Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study
Non-small cell lung cancer accounts for up to 85% of all lung cancer cases
Regeneron’s odronextamab recommended by CHMP to treat certain lymphomas
Follicular lymphoma and diffuse large B-cell lymphoma are collectively responsible for an estimated 283,000 global cases every year
Moderna/Merck share positive three-year results for investigational skin cancer vaccine
More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024